Archives of stem cell and therapy最新文献

Stem cell secretome-mediated alleviation of scalp psoriasis: A case report 干细胞分泌物介导的头皮银屑病缓解：病例报告

Archives of stem cell and therapy Pub Date : 2024-02-21 DOI: 10.46439/stemcell.5.019

Anjum Mahmood, Naman Somani, D. Patel, Rangnath Mishra, Anand Srivastsva

{"title":"Stem cell secretome-mediated alleviation of scalp psoriasis: A case report","authors":"Anjum Mahmood, Naman Somani, D. Patel, Rangnath Mishra, Anand Srivastsva","doi":"10.46439/stemcell.5.019","DOIUrl":"https://doi.org/10.46439/stemcell.5.019","url":null,"abstract":"Scalp psoriasis, a skin condition characterized by red, thickened (erythematous), well-demarcated patches or plaques with overlying silvery-white scales, affecting part or all of the scalp, is an autoimmune disease accompanied by itchy skin. The disease is associated with faulty functioning of adaptive and innate components of immune systems. The key proinflammatory cytokines mediating immunopathology of psoriasis are IL-17 and IL-23 which promote proliferation of Th 17 cells which in turn induce proliferation of keratinocytes leading to the disease. Standard management of psoriasis primarily targets the disease by suppression of inflammation using steroid based drugs. However, these are not enough to cure the disease. In recent years researchers have demonstrated the use of mesenchymal stem cells (MSCs) in treating autoimmune disorders and skin disorders. MSCs mediate skin regeneration by a plethora of mechanisms including immune modulation, angiogenesis, proliferation of mediator cells like fibroblasts, and by inhibition of proinflammatory pathways. The paracrine factors secreted by MSCs in surrounding environment like growth factors, cytokines, chemokines, and other signaling and regulatory molecules, act as key molecules in mediating anti-inflammatory responses. Here we describe a case report following the treatment of a patient suffering from scalp psoriasis using MSC- secreted molecules in the conditioned media. Both silvery scales and plaques on the scalp were significantly reduced within 4 weeks of topical application of the conditioned media. The patient remained disease free for 3 years of follow up. Our current results are in good agreement with those of our previous report where we reported complete amelioration of scalp psoriasis following the topical application of the conditioned media.","PeriodicalId":72292,"journal":{"name":"Archives of stem cell and therapy","volume":"13 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140442040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies. 推动HIV-1缓解：干细胞疗法的启示与创新。

Archives of stem cell and therapy Pub Date : 2024-01-01 DOI: 10.46439/stemcell.5.020

Aditi Chatterjee, Aerielle Matsangos, Olga S Latinovic, Alonso Heredia, Giovannino Silvestri

{"title":"Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies.","authors":"Aditi Chatterjee, Aerielle Matsangos, Olga S Latinovic, Alonso Heredia, Giovannino Silvestri","doi":"10.46439/stemcell.5.020","DOIUrl":"https://doi.org/10.46439/stemcell.5.020","url":null,"abstract":"Human immunodeficiency virus type 1 (HIV-1) continues to pose a significant global health challenge despite advances in combined antiretroviral therapy (cART), which has transformed HIV-1 infection from a fatal disease to a manageable chronic condition. However, cART is not curative, and its long-term use is associated with challenges such as pill burden, drug toxicities, and the emergence of drug-resistant viral strains. The persistence of active viral reservoirs necessitates lifelong treatment, highlighting the need for alternative therapeutic strategies capable of achieving HIV-1 remission or cure. Stem cell therapy has emerged as a promising approach to address these challenges by targeting latent viral reservoirs, restoring host immune function, and potentially achieving sustained viral suppression in the absence of cART. This review critically evaluates current scientific literature on stem cell therapies for HIV-1, focusing on three major approaches: 1) hematopoietic stem cell transplantation (HSCT), 2) gene therapy, and 3) cell-based immunotherapies. Each approach is examined in terms of its underlying mechanisms, clinical feasibility, recent advancements, and associated challenges. Furthermore, future research directions are discussed, emphasizing the optimization of the current treatment protocols, enhancement of safety and efficacy, and the importance of large-scale clinical trials with different cohorts (different HIV clades, different genders of participants, and pediatric HIV) to evaluate long-term outcomes that include effective and scalable HIV cure challenges. Collaborative efforts across multidisciplinary fields are needed to overcome existing barriers so to realize the full therapeutic potential of stem cell-based approaches for developing an effective and scalable remission or cure strategies.","PeriodicalId":72292,"journal":{"name":"Archives of stem cell and therapy","volume":"5 1","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The tumor dose sensitivity matrix and stem cells in head and neck cancer 头颈癌中的肿瘤剂量敏感基质和干细胞

Archives of stem cell and therapy Pub Date : 2023-12-21 DOI: 10.46439/stemcell.4.018

G. D. Wilson, Di Yan

引用次数: 0

Post-allogeneic stem cell transplant FLT3- targeted maintenance therapy: updates and considerations for clinical practice. 同种异体干细胞移植后FLT3靶向维持治疗:临床实践的更新和考虑。

Archives of stem cell and therapy Pub Date : 2022-01-01 DOI: 10.46439/stemcell.3.015

Jonathan Cohen, Richard T Maziarz

{"title":"Post-allogeneic stem cell transplant FLT3- targeted maintenance therapy: updates and considerations for clinical practice.","authors":"Jonathan Cohen, Richard T Maziarz","doi":"10.46439/stemcell.3.015","DOIUrl":"https://doi.org/10.46439/stemcell.3.015","url":null,"abstract":"Acute myeloid leukemia (AML) is characterized by multiple molecular and cytogenetic abnormalities, with increasing data to support clinical and prognostic implications to guide clinical decision making. One of the most well described mutations involves fms-like tyrosine kinase 3 (FLT3) that results in a constitutively active tyrosine kinase and is generally associated with poor prognosis involving shorter overall survival and higher rates of relapse. Advancements in targeted therapies have greatly influenced available treatment options in a landscape that has remained largely unchanged for the past five decades. Tyrosine kinase inhibitors (TKI), specifically FLT3-targeted therapies, are now integral treatment options for patients with this targetable mutation. As allogeneic hematopoietic cell transplant (alloHCT) remains the primary curative therapy for most adult AML patients, the goal is for eligible patients to proceed to transplant. However, post-alloHCT relapse remains exceedingly high even in patients achieving deep responses to therapy. Limited evaluation of FLT3-targeted TKIs as post-alloHCT maintenance therapy in FLT3-positive patients suggest improved outcomes and tolerable safety profiles, with ongoing studies further investigating second-generation agents. Thus, this commentary aims to review the role of post-alloHCT FLT3-targeted maintenance therapy and considerations for clinical practice.","PeriodicalId":72292,"journal":{"name":"Archives of stem cell and therapy","volume":"3 1","pages":"23-27"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10467947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Molecular signatures of aggressive pediatric liver cancer. 侵袭性儿童肝癌的分子特征。

Archives of stem cell and therapy Pub Date : 2021-01-01

Michael E Johnston, Nikolai Timchenko

{"title":"Molecular signatures of aggressive pediatric liver cancer.","authors":"Michael E Johnston, Nikolai Timchenko","doi":"","DOIUrl":"","url":null,"abstract":"Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer. Although genetic mutations have been reported in aggressive HBL, they represent a low level (1.9% per case) and are found mainly in two genes CTNNB1 and NRF2. Over the past 5 years, our liver biology and tumor group at Cincinnati Children's Hospital Medical Center has investigated molecular signatures of aggressive HBL by examination of fresh tissue specimens, which were studied immediately after surgery to preserve the integrity of key biochemical pathways. Summarization of these high quality HBL samples discovered several critical pathways that are specific for aggressive pediatric liver cancer. These pathways include three characteristics: Conversion of tumor suppressor proteins (TSPs) by posttranslational modifications into oncogenesActivation of specific chromosomal regions, i.e., Aggressive Liver Cancer Domains (ALCDs) within many oncogenes, resulting in increased expression of oncogenesPotential epigenetic mechanisms that open chromatin structure of oncogenes via ALCDs. This commentary summarizes our key findings and discusses development of potential ALCD-based therapeutic approaches.","PeriodicalId":72292,"journal":{"name":"Archives of stem cell and therapy","volume":"2 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39371813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mTOR: A possible therapeutic target against SARS-CoV-2 infection. mTOR：抗击 SARS-CoV-2 感染的可能治疗靶点。

Archives of stem cell and therapy Pub Date : 2021-01-01

Nabab Khan

引用次数: 0

Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy. 赖氨酸氧化酶抑制原发性骨髓纤维化:一个新的策略。

Archives of stem cell and therapy Pub Date : 2020-12-01 DOI: 10.46439/stemcell.1.005

Andrew Piasecki, Orly Leiva, Katya Ravid

{"title":"Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy.","authors":"Andrew Piasecki, Orly Leiva, Katya Ravid","doi":"10.46439/stemcell.1.005","DOIUrl":"https://doi.org/10.46439/stemcell.1.005","url":null,"abstract":"Primary myelofibrosis (PMF) is a type of myeloproliferative neoplasm (MPN) that portends a poor prognosis and has limited options for treatment. PMF is often driven by clonal mutations in one of three genes that regulate the JAK-STAT signaling pathway, leading to hyperactivation of this signaling pathway and over-proliferation of megakaryocytes (MKs) and their precursors. PMF presents with debilitating symptoms such as splenomegaly and weight loss. The few available treatments for PMF include a JAK2 inhibitor, ruxolitinib, which causes side effects and is not always effective. The extracellular matrix (ECM) and bone marrow (BM) microenvironment may play an important role in the pathogenesis of PMF. Lysyl oxidase (LOX), an enzyme that plays a key role in the ECM by facilitating the cross-linking of collagen and elastin fibers, has been shown to be upregulated in MKs of PMF mice and in PMF patients, suggesting its role in the progression of BM fibrosis. Recently, LOX has been identified as a potential novel therapeutic target for PMF and the development of new small molecule LOX inhibitors, PXS-LOX_1 and PXS-LOX_2, has shown some promise in slowing the progression of PMF in pre-clinical studies. Given that these inhibitors displayed an ability to target the dysregulation of the ECM via LOX inhibition, they show promise as therapeutic agents for an underappreciated aspect of PMF.","PeriodicalId":72292,"journal":{"name":"Archives of stem cell and therapy","volume":"1 1","pages":"23-27"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25493964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Role of the rapid delayed rectifier K⁺ current in human induced pluripotent stem cells derived cardiomyocytes. 快速延迟整流器K+电流在人诱导多能干细胞衍生的心肌细胞中的作用。

Archives of stem cell and therapy Pub Date : 2020-01-01 DOI: 10.46439/stemcell.1.003

Makarand Deo, Akwasi Akwaboah, Bright Tsevi, Jacqueline A Treat, Jonathan M Cordeiro

{"title":"Role of the rapid delayed rectifier K+ current in human induced pluripotent stem cells derived cardiomyocytes.","authors":"Makarand Deo, Akwasi Akwaboah, Bright Tsevi, Jacqueline A Treat, Jonathan M Cordeiro","doi":"10.46439/stemcell.1.003","DOIUrl":"https://doi.org/10.46439/stemcell.1.003","url":null,"abstract":"The action potential (AP) in cardiac tissue is important for initiating and coordinating contractions in the heart. In addition, the long refractory period minimizes the potential for developing extrasystoles and arrhythmias [1]. The AP is generated by coordinate changes in different ionic currents. In human (or canine) adult ventricular cells, the depolarization phase of the AP is mainly through the influx of Na+ and Ca2+ through specific voltage gated channels [2]. Repolarization of the AP is regulated by activation of a number of different K+ currents which play important roles in regulating the AP. These K+ currents include: (i) a Ca2+-independent transient outward K+ current (Ito), (ii) an inwardly rectifying K+ current (IK1), and (iii) the rapidly and slowly activating delayed rectifier K+ channel currents (IKr and IKs, respectively). Previous studies have demonstrated that there is an excess of several K+ currents necessary for cardiac repolarization such that a net outward current remains available for repolarization if one or more currents are reduced (repolarization reserve) [3– 5]. Therefore, cardiac tissue with a lower repolarization reserve is associated with a prolonged ventricular action potential and an increased incidence of developing arrhythmias [6]. Mutations in KCNH2 (the gene which encodes IKr) cause a decrease in the magnitude of IKr and are associated with Long QT syndrome [7,8]. Patients afflicted with Long QT have episodes of fainting, irregular heartbeats and an increased incidence of developing ventricular arrhythmias. Interestingly, many non-cardiac medications have also been shown to block IKr [9,10] which has resulted in drug companies extensively testing potential therapeutic compounds for IKr block prior to introduction to the market.","PeriodicalId":72292,"journal":{"name":"Archives of stem cell and therapy","volume":"1 1","pages":"14-18"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25383475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1